Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

NCT02593773 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02593773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02593773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 25, 2015
Completion date
March 21, 2017
Enrollment
86 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich's ataxia